Backed by Clinical Study Results
Think Clearer.
Remember More.
Feel Like Yourself.
BlueVibe is the only wearable combining dual 40Hz PEMF + blue light therapy — inspired by MIT's breakthrough research in cognitive enhancement.
Worn 1 hr/day · Non-invasive · Drug-free
"I stopped using my device for a week and realized how much it was actually helping." — Phase 1 Study Participant
Phase 1 Clinical Findings
Not a marginal effect.
A consistent signal.
In a completed 6-week Phase 1 study using validated PROMIS cognitive assessments, BlueVibe delivered results that would be virtually impossible by chance.
100%
of participants showed measurable cognitive improvement
0
participants declined or showed regression
<0.000001
p-value — results are not due to chance
6 wk
study duration, 1 hr/day, real-world conditions
Statistical significance confirmed via paired Wilcoxon signed-rank test. Full study report available on request.
How It Works
Two frequencies.
One wearable.
40Hz Pulsed PEMF
Pulsed electromagnetic fields at the clinically studied 40Hz frequency, delivered directly to the skin at the base of the skull — a gateway to key neurological pathways.
40Hz Blue Light
Flickering blue light targets visual and non-visual pathways (ipRGCs) to entrain natural brain rhythms associated with memory, focus, and clarity.
Gamma Entrainment (GENUS)
BlueVibe applies the Gamma Entrainment Using Sensory Stimulation approach — the same research direction pioneered at MIT's Picower Institute for Learning and Memory.
Strategic Placement
Worn at the occipital region (base of skull), targeting GV16 — a region with proximity to the brainstem, vagus nerve, and cerebrospinal fluid pathways.
Scientific Foundation
Inspired by
MIT research.
40Hz gamma brainwave activity is associated with memory, attention, and cognitive processing. Research from MIT's Picower Institute shows that 40Hz stimulation can produce measurable biological effects — including clearing amyloid-beta proteins linked to Alzheimer's disease.
Key findings from the 40Hz gamma literature include: reduction of amyloid-beta and tau proteins in animal models, activation of microglia, enhanced metabolic waste clearance, preservation of neuronal connections, and improvements in cognitive performance in experimental settings.
40Hz Gamma Entrainment
PEMF Technology
Dual Modality
Non-invasive
Drug-free
GENUS Protocol
What Participants Said
Real people.
Real results.
★★★★★
"It has lifted my depression. I feel like I can function better and think more clearly."
★★★★★
"There is a mental and emotional clarity that comes with using it. Hard to describe, but very real."
★★★★★
"My 83-year-old mother said she didn't feel depressed anymore. Her conversations were so massively improved I questioned if this was my mother or not."
★★★★★
"Anxiety greatly reduced. I feel like my short-term memory improved significantly."
★★★★★
"I stopped using it for a week and realized how much it was actually helping. I'm back on it now."
★★★★★
"The device was extremely easy to use. After about 10 seconds you forget you have it on."
Who It's For
BlueVibe supports relief
from 10 common symptoms.
Designed for people experiencing the early or ongoing effects of cognitive decline, mental fog, or emotional dysregulation.
Memory lapses
Brain fog
Word-finding difficulty
Short attention span
Mood swings
Anxiety & nervousness
Sleep disturbances
Social withdrawal
Confusion or disorientation
Low mental energy
The Device
Small device.
Big impact.
Dual 40Hz Modalities
PEMF + blue light, simultaneously delivered
Rechargeable
Lightweight, wireless, and USB rechargeable
1 Hour/Day Protocol
Simple use during rest or daily routines
FDA General Wellness Device
Non-invasive, drug-free, no side effects reported
Limited Availability
Ready to think clearer?
Our first production run sold out faster than expected. The April 15 release is now open for reservations — devices ship in the order reserved.
30-Day Satisfaction Guarantee
1-Year Warranty
Free U.S. Shipping
BlueVibe is an FDA general wellness device. It is not intended to diagnose, treat, cure, or prevent any disease.
Results may vary. Phase 1 study involved 41 matched participants over 6 weeks.